Estimating the long-term effects of HPV vaccination in Germany (Q39447224)

12 September 2017

Estimating the long-term effects of HPV vaccination in Germany (English)

1 reference

12 September 2017

0 references

5

1 reference

12 September 2017

J Horn

1

0 references

author name string

O Damm

2

1 reference

12 September 2017

M E E Kretzschmar

3

1 reference

12 September 2017

Y Deleré

4

1 reference

12 September 2017

A M Kaufmann

6

1 reference

12 September 2017

E Garbe

7

1 reference

12 September 2017

A Krämer

8

1 reference

12 September 2017

W Greiner

9

1 reference

12 September 2017

R T Mikolajczyk

10

1 reference

12 September 2017

language of work or name

English

0 references

publication date

18 March 2013

1 reference

12 September 2017

1 reference

12 September 2017

31

1 reference

12 September 2017

19

1 reference

12 September 2017

2372-2380

1 reference

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Genital human papillomavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

7 January 2021

HPV vaccine: Cervarix

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

The cost effectiveness of human papillomavirus vaccines: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Vaccination against multiple HPV types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Cost-effectiveness analysis of human papillomavirus-vaccination programs to prevent cervical cancer in Austria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Re: Epidemiological Study of Anti-HPV16/18 Seropositivity and Subsequent Risk of HPV16 and -18 Infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Prevalence and stability of antibodies to 37 human papillomavirus types--a population-based longitudinal study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Model for assessing human papillomavirus vaccination strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Epidemiologic natural history and clinical management of Human Papillomavirus (HPV) Disease: a critical and systematic review of the literature in the development of an HPV dynamic transmission model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Incidence of anogenital warts in Germany: a population-based cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Prevalence of sexually transmitted infections among female adolescents aged 14 to 19 in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Prevalence of low-risk and high-risk types of human papillomavirus and other risk factors for HPV infection in Germany within different age groups in women up to 30 years of age: an epidemiological observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Prevalence of human papillomavirus types in women screened by cytology in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

The cost-effectiveness of male HPV vaccination in the United States.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Sex-specific immunization for sexually transmitted infections such as human papillomavirus: insights from mathematical models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Economic evaluation of human papillomavirus vaccination in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

Incremental Impact of Adding Boys to Current Human Papillomavirus Vaccination Programs: Role of Herd Immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.03.006

10.1016/J.VACCINE.2013.03.006

7 January 2021

Identifiers

DOI

1 reference

12 September 2017

1 reference